Russia has announced the development of a revolutionary mRNA cancer vaccine, EnteroMix, which leverages artificial intelligence to create individualized treatment plans for patients. The vaccine, based on technology similar to that used in COVID-19 mRNA vaccines, utilizes AI-driven algorithms to generate personalized mRNA blueprints from patient genetic data, drastically reducing development time.
The Russian Federal Medical and Biological Agency (FMBA) confirmed the vaccine has completed preclinical trials, demonstrating safety and high effectiveness. Early clinical results showed tumors shrinking with no major side effects, according to reports. The vaccine is tailored to each patient’s RNA, targeting specific cancer types while preserving healthy tissue. Initial trials focused on colorectal cancer, with additional versions in development for glioblastoma and melanoma.
The project, led by the Ministry of Health’s National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology, was unveiled at the St Petersburg International Economic Forum (SPIEF 2025). Developers outlined a three-step process: algorithmic design of mRNA blueprints, synthesis at the Gamaleya Center, and immune response activation. AI integration accelerated personalized vaccine creation from months to hours.
The FMBA stated the vaccine is now in limited clinical use and awaits final approval for mass rollout. Russian officials highlighted the breakthrough as a major step in national healthcare strategy, with plans to distribute it free of charge. The initiative follows extensive research into oncological treatment complexities, aiming to adapt to emerging therapeutic challenges.